S. Korean stem cell firm enters into an agreement with Tiantan Puhua Neurological Hospital in China

Feb. 4, 2008 - PRLog -- RNL Bio, Co., LTD., (RNL), a leading stem cell therapeutics company of Korea, has entered today into an agreement with Tiantan Puhua Neurological Hospital (Puhua) in Beijing, China to establish a joint venture (the firm) and a new hospital to provide patients with stem cell therapeutics.
Dr. Sherwood Yang, Vice president of Puhua agreed with Dr. Jeong Chan Ra, president of CEO of RNL, to open a new stem cell clinic within Puhua hospital through the firm. The new hospital was tentatively named as “RNL-Puhua Stem Cell Medical Center, and will provide stem cell treatments of various degenerative disease including hair loss, aged face and osteoarthritis. The firm will also supply Puhua hospital with stem cell therapeutics for neurological condition such as spinal cord injury which Puhua is specialized for.
“We are very pleased to have a new hospital for stem cell therapy in China. It will not only advance the commercialization of out stem cell technology but contribute effective stem cell treatment to patients with obsolete complications”, said Dr. Ra.

About Tiantan Puhua Neurosurgical Hospital

Tiantan (Temple of Heaven) Puhua (treasure) Neurosurgical Hospital is a world-class neurological treatment facility in Beijing that is gaining renown as the world's foremost center for treatment of Parkinson's disease, brain injury, and a range of other neurological disorders through its groundbreaking stem cell therapy. To date, Tiantan Puhua Hospital has treated with stem cells over 60 international patients suffering from a range of neurological disorders.

About RNL Bio, CO., LTD.

RNL is a premier biotechnology company in Korea focused on stem cell therapeutics and life sciences technologies. Headquartered in Seoul with a recently opened state-of-the-art GMP facility, RNL is a publicly traded company on the Korean Stock Exchange (Code 003190) and strives to become a global leader in the development of stem cell therapeutics. In 2006 RNL established wholly owned US subsidiary, RNL Biostar, for clinical development in the US and for licensing its technologies in North and South America.

For more information:

Jin Han Hong, Ph.D., Director (HONGJH@RNL.CO.KR)
RNL Biostar, Inc
9700 Great Seneca Hwy
Rockville, MD 20850

Website: rnl.co.kr/eng/